Methods of using GLP-1 receptor agonists to treat pancreatitis
AssigneeAmylin Pharmaceuticals, Inc.
InventorsKrystyna Tatarkiewicz, David G. Parkes, Denis Roy, Bronislava Gedulin
Life of this patent
Estimating the term…
Abstract
The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide.
Claims18
A method for treating acute pancreatitis in a human in need thereof comprising administering to the human a therapeutically effective amount of exenatide to treat acute pancreatitis.
A method for treating pancreatitis in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a GLP-1 receptor agonist to treat pancreatitis.
Dependencies are inferred from the claim text.